| September 1 |
Novavax Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate |
| September 1 |
ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis |
| September 1 |
TransPharma Announces Successful Completion of Phase 2 Trial of ViaDerm-hPTH (1-34) in Postmenopausal Women with Osteoporosis |
| September 1 |
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix in Acute Coronary Syndrome Patients Undergoing Angioplasty |
| September 1 |
Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients |
| September 1 |
Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes |
| September 2 |
Crestor Reduced Risk of Cardiovascular Events in Elderly Patients in New Analysis of Jupiter |
| September 2 |
Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain |
| September 2 |
Acceleron Pharma's ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial |
| September 2 |
New Results In Angina Patients: Fewer Heart Attacks With Procoralan (Ivabradine) |
| September 3 |
Enabling Capabilities of Inovio Biomedical's Electroporation Delivery Technology with SIV DNA Vaccine Confirmed in Collaborative Study With National Cancer Institute |
| September 3 |
HPV Vaccine Could Prevent Breast Cancer: Australian Research |
| September 3 |
Novartis MF59 Adjuvanted Cell Culture-Based Vaccine Shows Strong Immune Response In A(H1N1) Clinical Trials |
| September 3 |
Curis Announces GDC-0449 Phase I Clinical Data Published in New England Journal of Medicine |
| September 4 |
Novel Evidence-Based Systemic Lupus Erythematosus (SLE) Responder Index Described in Peer Reviewed Publication as Potentially Significant Advance in Lupus Drug Development |
| September 4 |
Array BioPharma Announces Top-Line Results from Rheumatoid Arthritis Phase 2 Trial |
| September 4 |
NovaDel Article Published in Headache: The Journal of Head and Face Pain |
| September 4 |
PharmAthene Presents Data for Valortim Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference |
| September 4 |
Large Thighs Protect Against Heart Disease and Early Death |
| September 4 |
Gene Signal and Collaborators Publish GS-101 Clinical Data Suggesting Safe and Effective Inhibition of Abnormal Ophthalmic Blood Vessel Growth |
| September 4 |
Promising Results of Drug Trial Could Herald a Replacement for Popular Blood Thinner |
| September 4 |
LIVALO Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia |
| September 6 |
Study Shows Livalo is not Affected by Co-Administration of Itraconazole |
| September 6 |
Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra in RA |
| September 6 |
Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrine's Cotara for Treatment of Brain Cancer |
| September 7 |
Rheumatoid Arthritis (RA) Patients Taking Enbrel Keep Working for Longer |
| September 8 |
XenoPort Reports Preliminary Results From a Safety and Tolerability Trial of Arbaclofen Placarbil in Patients With Acute Back Spasms |
| September 8 |
Opexa Reports Additional Favorable Data with Tovaxin for Multiple Sclerosis |
| September 8 |
New Teva Data Highlights Advances in MS Treatment Research |
| September 8 |
Emisphere Technologies Announces Publication in Clinical Pharmacology and Therapeutics of Encouraging Data from an Independent Clinical Study of an Oral Eligen-GLP-1 Formulation on Glucose Homeostasis |
| September 8 |
NanoBio's Vaccine Adjuvant Platform Demonstrates Robust Immunity and Cross Protection Against Influenza |
| September 8 |
Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101 |
| September 8 |
Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials |
| September 9 |
VIVUS to Host Conference Call and Webcast Discussion of Qnexa Phase 3 Results |
| September 9 |
Vivus Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities |
| September 9 |
Cytheris to Present Interim Data from INSPIRE HIV Multicenter Study in Oral Late Breaker at ICAAC |
| September 9 |
Ore Pharmaceuticals Announces Upcoming Publication of Research Study on ORE1001 |
| September 9 |
Affymax Provides Phase 3 Program Update for Investigational Drug, Hematide, to Treat Anemia in Chronic Renal Failure |
| September 9 |
Largest comparative hepatitis C study confirms treatment effectiveness... |
| September 10 |
Acorda Therapeutics Announces Interim Analysis of Two-Year Efficacy and Safety Data from Phase 3 Fampridine-SR Extension Study |
| September 10 |
Reliability and Validity of Dyax's Novel Patient Reported Outcome Measures (PROs) Affirmed in Published Study |
| September 10 |
Dexamethasone-Based Therapy Shows Improvement In Survival For Children With Acute Lymphoblastic Leukaemia |
| September 10 |
New research indicates 95% of patients are in moderate to severe chronic pain despite one year of treatment |
| September 10 |
QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy |
| September 10 |
Protox announces positive 12 month Phase 2 BPH results |
| September 10 |
MAP Pharmaceuticals' Analysis of Positive Phase 3 Levadex Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society |
| September 10 |
Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients |
| September 10 |
Virus Responsible For Deadly Brain Disease Found In MS Patients Treated With Natalizumab |
| September 10 |
Zelrix, a Novel Transdermal Patch for Migraine, Found to Provide Rapid, Consistent, and Sustained Relief for Migraine Sufferers in Phase III Trial |
| September 10 |
Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 |
| September 10 |
Acceleron Pharma's ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial |
| September 10 |
Key Data Related to Plexxikon's Lead Oncology Program PLX4032 to Be Presented at ECCO15 / ESMO34 2009 Conference |
| September 11 |
Variation Biotechnologies to Present Positive Influenza Vaccine Data at the 49th Annual ICAAC Meeting |
| September 11 |
New WHO Data Underscores Global Threat of the World's Leading Child Killer |
| September 11 |
Results from IMPROVE Study Show MRI Benefits of Rebif Seen Early in Relapsing-Remitting Multiple Sclerosis Treatment and Sustained Over Time |
| September 11 |
Data Supporting Unique Efficacy of Tysabri Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis |
| September 11 |
Encouraging Phase II Results With Teriflunomide In Patients With Relapsing Multiple Sclerosis |
| September 11 |
New Data From CLARITY Study on Disease Activity in MS Patients Who Received Cladribine Tablets Presented at 25th ECTRIMS Congress |
| September 11 |
Fewer Injection Site Reactions in Patients Using Avonex Versus Sub-cutaneous Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis |
| September 11 |
Laquinimod Immunomodulatory Action Confers Both Neuroprotective and Anti-Inflammatory Properties |
| September 11 |
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta |
| September 11 |
Genzyme's Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data |
| September 11 |
Statement by Dr. Anthony Fauci, Director, National Institute of Allergy and Infections Diseases, NIH, Regarding Early Results from Clinical Trials of 2009 H1N1 Influenza Vaccines in Healthy Adults |
| September 11 |
Instanyl (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer Pain |
| September 11 |
Data to be Presented on Multiple Targacept NNR Therapeutics at Society for Neuroscience Satellite Symposium |
| September 11 |
Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 |
| September 14 |
Variation Biotechnologies Flu Vaccine Provides Robust Immune Response, Broad Protection against H1N1 Influenza Strain |
| September 14 |
Aradigm Presents Data Demonstrating Significant Antibacterial Concentrations and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin |
| September 14 |
Concert Pharmaceuticals Presents Clinical Results Demonstrating Reduced Drug-Drug Interactions with a Deuterium-Modified Compound |
| September 14 |
Pandemic (H1N1) 2009 Influenza Update: Initial Results from First Clinical Trial of GSK?s H1N1 Adjuvanted Vaccine |
| September 14 |
Kenta Biotech Reports Phase IIa Data with Lead Candidate Panobacumab in Hospital-Acquired Pneumonia |
| September 14 |
ExonHit Presents Promising First Patient Results for EHT 0202, Its Alzheimer's Candidate Drug |
| September 14 |
Altair Therapeutics Reports Successful Phase I Study of Inhaled AIR645 |
| September 14 |
Salix Pharmaceuticals Announces Statistically Significant Results for Both the Primary and Key Secondary Analyses Of Rifaximin in the Treatment of Non-Constipation Irritable Bowel Syndrome in Two Phase 3 Trials (Target 1 and Target 2) |
| September 14 |
New, Long-Term Data for Odanacatib, Merck's Investigational Cat K Inhibitor, Showed Positive Results in Treating Osteoporosis |
| September 15 |
Acorda Therapeutics Announces Data on Retention Rates and Safety from Two Phase 3 Fampridine-SR Extension Studies |
| September 15 |
Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients |
| September 15 |
Argenta Discovery Publishes Positive Data From a Phase II Proof of Concept Trial with Co-Administration of Inhaled ADC4022 Plus Budesonide Study in COPD |
| September 15 |
Novartis investigational bronchodilator QAB149 improves lung function and reduces breathlessness compared to tiotropium in patients with COPD |
| September 15 |
New efficacy data on Basilea's novel antibiotic against multi-resistant Gram-negative bacteria presented at ICAAC |
| September 15 |
Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with Bazedoxifene |
| September 15 |
Kamada Presents Data on Inhaled Alpha-1 Antitrypsin in Cystic Fibrosis Patients at the European Respiratory Society Meeting 2009, Vienna |
| September 15 |
Merck's ISENTRESS (raltegravir) Tablets Studied in Comparison to Efavirenz in Combination Therapy Through 96 Weeks in HIV-1 Treatment-Naïve Patients |
| September 15 |
Pivotal Data Demonstrating Efficacy of Darusentan in Treating Resistant Hypertension Published in The Lancet |
| September 15 |
Ipsen: Encouraging Preliminary New Data Available for the Treatment of Short Stature Children with Low IGF-1 Levels |
| September 15 |
Encouraging Preliminary New Data Available for the Treatment Of Short Stature Children With Low IGF-1 Levels |
| September 15 |
QVA149 Phase II data presented at the European Respiratory Society annual meeting |
| September 15 |
Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting |
| September 15 |
Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress |
| September 15 |
BioAlliance Pharma Makes Four Presentations at the 49th ICAAC Meeting Including Three Phase III Study Results with miconazole Lauriad and One with Its Integrase Inhibitor |
| September 15 |
Cytheris Announces Interim Data from INSPIRE Study Showing Interleukin-7 (CYT107) Induces Dose-Dependent and Sustained Increase of CD4 T Cells in Chronic HIV-Infected Patients |
| September 15 |
Medivir Has Presented Lipsovir at the Ongoing 49th ICAAC Meeting in San Francisco, USA |
| September 15 |
Achaogen Announces ACHN-490 Clinical Data at the 49th Annual ICAAC Meeting |
| September 15 |
NanoBio Presents Key Data on the Use of Nanoemulsions to Treat Burn Wound Infections |
| September 16 |
QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting |
| September 16 |
Schering-Plough Reports Data From Saphris (asenapine) Long-Term Schizophrenia Relapse Prevention Study |
| September 16 |
Potential Once-weekly Asthma Treatment Found Safe, Well-Tolerated in Study |
| September 16 |
Enobia Announces Positive Clinical Results With ENB-0040, a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia |
| September 16 |
ExonHit presents promising first patient results for EHT 0202, its Alzheimer's candidate drug |
| September 16 |
Detailed Data From Vical's TransVax CMV Vaccine Phase 2 Trial Presented in Late-Breaker Session at ICAAC |
| September 16 |
Treatment with Insulin or Metformin Does Not Reduce Inflammatory Biomarkers for Patients With Diabetes |
| September 16 |
Medivir Presented Its Cathepsin K Program at the Ongoing 31st ASBMR Meeting in Denver, USA |
| September 17 |
Bioheart Inc. Announces Positive Results in the MARVEL Phase II/III Clinical Trial |
| September 17 |
TYSABRI Data: ECTRIMS (European Committee for the Treatment and Research in Multiple Sclerosis) |
| September 17 |
18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkin's Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherapy |
| September 17 |
Positive Phase IIb Results for GSK1838262 (XP13512) Reported for Neuropathic Pain Associated with Post-Herpetic Neuralgia |
| September 17 |
Anemic Patients With MDS Gain Long-Term Benefits From Erythropoietin and Myeloid Growth Factor Hormones |
| September 17 |
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance |
| September 17 |
STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial |
| September 18 |
Algeta to present new clinical data from three phase II trials with Alpharadin at ECCO 15 - 34th ESMO Congress |
| September 18 |
Study shows MabThera maintenance treatment delays disease progression in patients with incurable lymphoma |
| September 18 |
Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December |
| September 18 |
Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress |
| September 18 |
Pfizer To Present Research On Established Therapies And New Approaches To Cancer Treatment Using Investigational Agents |
| September 19 |
Study Demonstrates That QVAR is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options |
| September 19 |
First Human Data on Deuterlium-Modified Drugs This Week |
| September 19 |
Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) |
| September 21 |
ARIAD Announces Clinical Data from Phase 1 Study of Its Investigational mTOR Inhibitor, Ridaforolimus, in Combination with Bevacizumab |
| September 22 |
Dynavax Announces HEPLISAV Data to Be Presented at IDSA Medical Conference |
| September 22 |
Survival Benefit Maintained in Long Term Follow-up of IES with Pfizer's AROMASIN (Exemestane Tablets) |
| September 22 |
Provectus Completes Treatment of All Patients in Phase 2 Trial of PV-10 for Metastatic Melanoma |
| September 22 |
Impax Pharmaceuticals Reports Positive Results of Phase II Trial of IPX066, a Novel Formulation of Carbidopa-Levodopa for Parkinson's Disease |
| September 22 |
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases |
| September 22 |
Incyte Announces Positive Top-Line Phase IIb Results for Topical INCB18424 in Psoriasis |
| September 22 |
Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients |
| September 22 |
Avastin could play an important role in improving the daily lives of patients with the most aggressive form of brain cancer |
| September 22 |
Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors |
| September 22 |
'Headache' Publication Describes Potential Mechanistic Rationale for Levadex Favorable Adverse Event Profile |
| September 22 |
New results from ADVANCE trial at International Diabetes Federation (IDF) Congress 2009 |
| September 22 |
New phase II data presented at ECCO 15 - 34th ESMO Congress reinforces exciting potential of Algeta's Alpharadin as a new treatment for bone metastases in cancer patients |
| September 22 |
Important data for NicOx' naproxcinod published in the American Journal of Cardiology |
| September 22 |
Abbott's XIENCE V Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial |
| September 23 |
Idera Pharmaceuticals Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva and Avastin in Non-Small Cell Lung Cancer |
| September 23 |
Plexxikon Announces Encouraging Data from Phase 1 Extension Study of PLX4032 Showing Objective Responses in Metastatic Melanoma Patients |
| September 23 |
Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study |
| September 23 |
Data Presented from Two Phase 3 Erbitux Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress |
| September 23 |
From inoperable disease to potentially life saving surgery - new Avastin data gives hope to colorectal cancer patients with liver metastases |
| September 23 |
Initial COIN Study Results Presented at European Oncology Congress |
| September 23 |
Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer |
| September 23 |
AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer |
| September 23 |
Lux Biosciences Reports Phase 1 Safety Results and Open Label Efficacy Results for LX214, a Potential Best-in-Class Treatment for Dry Eye |
| September 23 |
Elixir Medical Corporation Announces Positive First-In-Man Results for Three Drug Eluting Coronary Stent Systems with Durable and Bioabsorbable Polymers |
| September 23 |
SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS and TAXUS Express Stents |
| September 23 |
Abbott's XIENCE V Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial |
| September 23 |
Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia |
| September 23 |
TAXUS Liberte Stent Continues to Demonstrate Significant Improvements Over TAXUS Express Stent in Small Vessels and Long Lesions |
| September 23 |
NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress |
| September 23 |
Vectibix in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer |
| September 23 |
Denosumab Demonstrates Superiority Over Zometa in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients |
| September 23 |
Results of ADAGIO Study with AZILECT in Parkinson's Disease Published in New England Journal of Medicine |
| September 24 |
Two Phase Iii Studies Confirm Efficacy Of Iressa In EGFR MUTATION+ NSCLC |
| September 24 |
Results of ADAGIO study with Azilect in Parkinson's disease published in The New England Journal of Medicine |
| September 24 |
IAVI Statement on Results of Phase III ALVAC-AIDSVAX Trial in Thailand |
| September 24 |
Alkermes Announces Amylin and Lilly Will Present More than 20 Studies for Exenatide at EASD 2009 |
| September 24 |
Genzyme's Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia |
| September 24 |
Interim Results From Phase Iii Trist Study Of Trovax In Renal Cancer |
| September 24 |
Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial |
| September 24 |
NEVO? Sirolimus-Eluting Coronary Stent Associated with Significantly Less Chest Pain at Six Months Than Taxus Liberte Stent |
| September 24 |
Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting |
| September 25 |
Vectibix in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer |
| September 25 |
Active Biotech's Prostate Cancer Project TASQ Featured in British Journal of Cancer |
| September 25 |
Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma |
| September 25 |
Prime-Boost Vaccine Study Shows Modest Effect in Preventing HIV |
| September 25 |
Angiomax Reduced Cardiac Mortality by 41%; Reduced Overall Mortality by 25% in Severe Heart Attack Patients Following Angioplasty |
| September 26 |
Chelsea Therapeutics Reports Preliminary Phase III Data of Droxidopa for Treatment of Symptomatic Neurogenic Orthostatic Hypotension |
| September 26 |
ECCO/ESMO Highlights Plexxikon Melanoma Data Given 70% Response Rate |
| September 27 |
Study Shows Superior Efficacy for Taxus Express Stents Compared to Bare-Metal Stents in Heart Attack Patients at Two Years |
| September 29 |
Alimera Reports Safety and Efficacy Results From the 18-Month Interim Readout of the Human PK Iluvien(R) Study |
| September 29 |
Hythiam Announces First Peer-Reviewed Publication of Statistically Significant Results from Randomized, Double-Blind, Placebo-Controlled Study |
| September 29 |
Updated Single Agent Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Carcinoma Reported at the Eighth International Kidney Cancer Symposium |
| September 29 |
New Data Suggest that Gelnique (oxybutynin chloride) gel 10% Does Not Impact Cognition among Healthy Older Adults |
| September 29 |
pSivida Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien Study |
| September 29 |
Acrux Announces Successful AXIRON Phase III Trial Results |
| September 29 |
Sanofi-aventis launches major insulin research program in partnership with the international scientific community |
